Can some endometrial cancer patients skip lymph node surgery?
NCT ID NCT07368205
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study is looking at 350 women with early-stage endometrial cancer to see if doctors can better predict who really needs lymph node removal during surgery. Participants receive standard care and are followed for three years. The goal is to find out if some patients can safely skip this step without affecting their treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors identify which endometrial cancer patients can safely avoid lymph node removal during surgery, reducing side effects.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly change care yet. Results depend on real-world data and may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 350 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Feb 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with histologicaly confirmed endometrial cancer.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Women ≥18 years with newly diagnosed endometrial cancer (any histology) * Undergoing primary surgical management * Preoperative expert ultrasound, CT scan (could be waived in low risk cases) * Preoperatively early-stage (stage I-II) of EC * SLN mapping attempted intraoperatively * FFPE tumor tissue available for molecular and IHC testing from biopsy * Signed informed consent with the participation in the study Exclusion Criteria: * Neoadjuvant treatment * Recurrent or metastatic disease at diagnosis * Inadequate imaging or tissue samples * Cancer synchronous duplicity * Prior oncological treatment within the last five years
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Hospital Hradec Kralove
RECRUITINGHradec Králové, Czechia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shorter, personalized radiation may target endometrial cancer with fewer side effects
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- Can a Weight-Loss drug and an IUD treat early uterine cancer without surgery?
- Your gut bacteria may hold the key to whether immunotherapy works
- Can a guided missile for chemo hit tumors harder and spare healthy tissue?
- Can an oral drug that starves tumors help Hard-to-Treat cancers?